eISSN: 2450-4459
ISSN: 2450-3517
Lekarz POZ
Current issue Archive Manuscripts accepted About the journal Abstracting and indexing Subscription Contact Instructions for authors
5/2017
vol. 3
 
Share:
Share:
more
 
 
abstract:
Review paper

Fight the big belly with valsartan. Can antihypertensive medications affect the related parameters with obesity?

Dorota Zozulińska-Ziółkiewicz

Online publish date: 2017/11/29
View full text
Get citation
ENW
EndNote
BIB
JabRef, Mendeley
RIS
Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
 
Abdominal obesity is a manifestation of severe metabolic disturbances with the common background that is insulin resistance. Hypertension often accompanies obesity. When choosing antihypertensive drugs in obese patients physicians should take into account its impact on metabolism. Activation of the abdominal obesity-induced renin–angiotensin–aldosterone system justifies the preference of antihypertensive drugs blocking this system, i.e. converting enzyme inhibitors and angiotensin receptor blockers. Based on inference analysis of clinical trials and the results of experimental studies, the slogan Fight the big belly with valsartan becomes understandable.
keywords:

abdominal obesity, hypertension, renin–angiotensin–aldosterone system, valsartan

Quick links
© 2020 Termedia Sp. z o.o. All rights reserved.
Developed by Bentus.
PayU - płatności internetowe